Current Status of HbA1c Biosensors

Hua, Lin; Yi, Jun

doi:10.3390/s17081798

Cited by 37 publications

(13 citation statements)

References 77 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The HbA1c-lowering effect of dapagliflozin was greater among patients with stable concentrations relative to all 72 patients (Table 2). HbA1c is formed via non-enzymatic glycosylation reactions, and it reflects the ambient glucose level over the past 2-3 months [19,20]. Therefore, maintaining the glucose level seems to be important in lowering HbA1c levels.…”

Section: Discussionmentioning

confidence: 99%

Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus

et al. 2022

View full text Add to dashboard Cite

This study was conducted to evaluate the long-term plasma concentration profiles of dapagliflozin and its effects on the glycated hemoglobin (HbA1c) level, body weight, and estimated glomerular filtration rate (eGFR) in 72 Japanese outpatients with type 2 diabetes mellitus (T2DM) receiving metformin and a dipeptidyl peptidase-4 inhibitor. At baseline, HbA1c level, body weight, and eGFR were 6.9 ± 0.6%, 77.9 ± 13.5 kg, and 78.8 ± 20.7 mL/min/1.73 m2, respectively. A once-daily oral dose of 5 mg dapagliflozin was administered, and its trough plasma concentrations were evaluated at 1, 3, 6, 9, and 12 months. In this study, the patients with stable dapagliflozin concentrations were defined, based on a well-organized clinical trial, as those with average plasma concentrations of 2–5 ng/mL with a coefficient of variation <30%; these values were achieved if patients complied with their once-daily dosage. Multivariate analysis showed a significant decrease in the HbA1c levels among patients with stable concentrations (−0.6 ± 0.4%, p < 0.01), which was greater than the mean change among all 72 patients (−0.2 ± 0.5%, p < 0.01). The patients’ mean body weight also decreased (−2.3 ± 4.0 kg, p = 0.060). Average plasma concentrations ranged from 1.6 to 11.8 ng/mL; however, multivariate analysis indicated it was unrelated to the HbA1c-lowering effect. In conclusion, the long-term stability of plasma dapagliflozin concentration was important in lowering HbA1c level, and a once-daily oral dose of 5 mg was sufficient in achieving this effect.

show abstract

Section: Discussionmentioning

confidence: 99%

Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Experiments have shown that increasing Treg cells reduces the infiltration of macrophages in adipose tissue, which is important for alleviating IR. 172 In addition, the damage to the diversity and amount of SCFAs-producing bacteria in the gut increases the glycated hemoglobin (HbA1c) level in T2DM patients, 173 a kind of protein that represents the average plasma glucose levels over the past 2 to 3 months, 174 suggesting that the poor glycemic control.…”

Section: Gut Microbiota Dysbiosis and The Risk Factors For Ischemic S...mentioning

confidence: 99%

Relationships Among Gut Microbiota, Ischemic Stroke and Its Risk Factors: Based on Research Evidence

Huang¹,

Cai²,

Liu³

et al. 2022

IJGM

View full text Add to dashboard Cite

Stroke is a highly lethal disease and disabling illness while ischemic stroke accounts for the majority of stroke. It has been found that inflammation plays a key role in the initiation and progression of stroke, and atherosclerotic plaque rupture is considered to be the leading cause of ischemic stroke. Furthermore, chronic inflammatory diseases, such as obesity, type 2 diabetes mellitus (T2DM) and hypertension, are also considered as the high-risk factors for stroke. Recently, the topic on how gut microbiota affects human health has aroused great concern. The initiation and progression of ischemic stroke has been found to have close relation with gut microbiota dysbiosis. Hence, this manuscript briefly summarizes the roles of gut microbiota in ischemic stroke and its related risk factors, and the practicability of preventing and alleviating ischemic stroke by reconstructing gut microbiota.

show abstract

“…Development in HbA1c biosensors is also ongoing, and it is expected that in the future patients will have access to personal point-of-care HbA1c measurements that can be streamed to smartphones [37].…”

Section: Diabetes Managementmentioning

confidence: 99%

Digital Health in Cardiac Rehabilitation and Secondary Prevention: A Search for the Ideal Tool

Falter

Scherrenberg

Dendale

2020

Sensors

View full text Add to dashboard Cite

Digital health is becoming more integrated in daily medical practice. In cardiology, patient care is already moving from the hospital to the patients’ homes, with large trials showing positive results in the field of telemonitoring via cardiac implantable electronic devices (CIEDs), monitoring of pulmonary artery pressure via implantable devices, telemonitoring via home-based non-invasive sensors, and screening for atrial fibrillation via smartphone and smartwatch technology. Cardiac rehabilitation and secondary prevention are modalities that could greatly benefit from digital health integration, as current compliance and cardiac rehabilitation participation rates are low and optimisation is urgently required. This viewpoint offers a perspective on current use of digital health technologies in cardiac rehabilitation, heart failure and secondary prevention. Important barriers which need to be addressed for implementation in medical practice are discussed. To conclude, a future ideal digital tool and integrated healthcare system are envisioned. To overcome personal, technological, and legal barriers, technological development should happen in dialog with patients and caregivers. Aided by digital technology, a future could be realised in which we are able to offer high-quality, affordable, personalised healthcare in a patient-centred way.

show abstract

Current Status of HbA1c Biosensors

Cited by 37 publications

References 77 publications

Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus

Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus

Relationships Among Gut Microbiota, Ischemic Stroke and Its Risk Factors: Based on Research Evidence

Digital Health in Cardiac Rehabilitation and Secondary Prevention: A Search for the Ideal Tool

Contact Info

Product

Resources

About